<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0886F2A5-22F1-47BA-8EF4-5BE4B85FD6B5"><gtr:id>0886F2A5-22F1-47BA-8EF4-5BE4B85FD6B5</gtr:id><gtr:name>University of Technology Sydney</gtr:name><gtr:address><gtr:line1>Faculty of Information Technology</gtr:line1><gtr:line2>PO Box 123 Broadway</gtr:line2><gtr:line3>NSW 2007</gtr:line3><gtr:line4>Sydney</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4859AC99-E237-4D8C-887B-E1A01E5269F3"><gtr:id>4859AC99-E237-4D8C-887B-E1A01E5269F3</gtr:id><gtr:name>Arno Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E"><gtr:id>9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E</gtr:id><gtr:name>St George's Healthcare NHS Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Institute of Translational Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0886F2A5-22F1-47BA-8EF4-5BE4B85FD6B5"><gtr:id>0886F2A5-22F1-47BA-8EF4-5BE4B85FD6B5</gtr:id><gtr:name>University of Technology Sydney</gtr:name><gtr:address><gtr:line1>Faculty of Information Technology</gtr:line1><gtr:line2>PO Box 123 Broadway</gtr:line2><gtr:line3>NSW 2007</gtr:line3><gtr:line4>Sydney</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4859AC99-E237-4D8C-887B-E1A01E5269F3"><gtr:id>4859AC99-E237-4D8C-887B-E1A01E5269F3</gtr:id><gtr:name>Arno Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E"><gtr:id>9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E</gtr:id><gtr:name>St George's Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E6728858-2442-495C-831C-2B381D2136EB"><gtr:id>E6728858-2442-495C-831C-2B381D2136EB</gtr:id><gtr:firstName>William</gtr:firstName><gtr:surname>Hope</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001760"><gtr:id>C4B5FE0E-B131-4459-AB0B-8B2EC9669932</gtr:id><gtr:title>Cryptococcal meningitis: addressing an urgent global health problem using a translational pharmacological approach</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001760</gtr:grantReference><gtr:abstractText>Cryptococcal meningitis is a frequently lethal fungal infection of the lining of the brain. The most common predisposing condition is advanced AIDS, although cryptococcal meningitis may occur in other circumstances where there is impairment of systemic immunity. Cryptococcal meningitis affects approximately one million people in the world each year and the mortality rate is 60-70%. Recent estimates suggest that cryptococcal meningitis kills more people in sub-Saharan Africa each year than tuberculosis. Unfortunately, there are relatively few active antifungal drugs to treat this infection and each has significant limitations. The best clinical outcomes result from early rapid killing of the fungus in the brain. In the UK this is usually achieved with induction therapy that consists of 2-weeks of intravenous antifungal therapy. Unfortunately, in much of the developing world, it is simply not possible to administer intravenous drugs for any length of time. Hence, the best therapy is not given and clinical outcomes are persistently unsatisfactory. 
This research aims to develop new induction regimens that can be used in the developing world. Shorter regimens (even a single day) would facilitate the use of optimal induction therapy and represents an important mechanism to improve clinical outcomes. We will conduct all our research using well-validated experimental models of cryptococcal meningitis. We will study antifungal agents alone and in combination to understand the relationship between concentrations of drug(s) in the brain and the killing of the fungus. We will then use mathematical models and computer simulation techniques to identify human antifungal regimens that we predict will result in the same or better activity to the current standard of care that is delivered in the UK. After the completion of this research, we will seek further funding to conduct clinical trials in subSaharan Africa to test these new regimens. Our research offers the real possibility of making significant advances for the care of patients with a lethal and neglected disease.</gtr:abstractText><gtr:technicalSummary>BACKGROUND: 
Cryptococcal meningitis is an urgent global health problem. The goal of induction antifungal therapy is to achieve rapid fungal killing because this is associated with improved clinical outcomes. In the UK this is usually achieved with 2-weeks of i.v. amphotericin B deoxycholate?flucytosine. In much of the developing world there are inadequate resources to enable prolonged administration of i.v. drugs or the detection and management of drug-related toxicity. The inability to give i.v. induction therapy is a significant therapeutic obstacle. Importantly, however, the use of shorter induction regimens that still achieve rapid fungicidal activity would facilitate the administration of optimal antifungal therapy in resource poor settings. This research will use well-validated experimental models of cryptococcal meningitis and state-of-the-art mathematical modelling techniques to identify candidate antifungal regimens for resource-poor settings. These regimens can then be immediately expedited for study in clinical trials.
AIMS:
Aim #1. Identify novel induction regimens of amphotericin B deoxycholate that result in the same or better fungicidal activity as 0.7 mg/kg/day administered to humans for 14 days 
Aim #II. Define the optimal dosage, schedule of administration and shortest duration of therapy of lipid preparations of amphotericin B that results in near maximal fungicidal activity
Aim #III. Define optimal combination regimens and the shortest duration of therapy that results in the same or better fungicidal activity as standard antifungal combinations administered for 14 days

METHODS: A well-validated murine model of cryptococcal meningitis will be used. The biomarker will be the fungal density in the brain. Pharmacokinetic and pharmacodynamic relationships will be elucidated by studying a range of clinically relevant regimens. Mathematical models that describe the time-course of drug concentrations (in serum and brain) and the associated antifungal effect will be fitted to each dataset. These mathematical models will be used to humanise the mouse in silico (i.e. in a simulator, drug will be given to a virtual mouse to generate a human-like concentration-time profile). The predicted antifungal effect resulting from these innovative regimens will be determined. Key findings will be further validated in a rabbit model of cryptococcal meningitis. 
SCIENTIFIC AND MEDICAL OPPORTUNITIES: This research will deliver: (1) new induction regimens for amphotericin B deoxycholate; (2) new induction regimens for lipid preparations of amphotericin B; and (3) new induction antifungal combination regimens. This proposal offers the real possibility to deliver a step change in the management of cryptococcal meningitis for the developing world.</gtr:technicalSummary><gtr:fund><gtr:end>2015-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-09-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>886688</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Thomas Harrison</gtr:description><gtr:id>47A7FB41-FE7F-442E-A37A-B6E4534D8655</gtr:id><gtr:impact>manuscript submitted for publication</gtr:impact><gtr:outcomeId>rEscLYY2rdz-1</gtr:outcomeId><gtr:partnerContribution>input into clinical relevance of experimental work</gtr:partnerContribution><gtr:piContribution>Co-author on recent paper submitted for publication on cryptococcal meningitis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:department>Oxford University Clinical Research Unit Vietnam (OUCRU)</gtr:department><gtr:description>Thuy Le</gtr:description><gtr:id>0E45B904-45A8-47C2-AE25-2A8085252832</gtr:id><gtr:impact>research underway</gtr:impact><gtr:outcomeId>546218e18e62b0.11369306-1</gtr:outcomeId><gtr:partnerContribution>clinical trial funded by MRC</gtr:partnerContribution><gtr:piContribution>measurement of itraconazole and voriconazole , and PKPD modelling in patients with disseminated Penicillium marneffei</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine Duke</gtr:department><gtr:description>John Perfect</gtr:description><gtr:id>F97A8E55-0ECA-409C-B4BC-7ED97738E4E8</gtr:id><gtr:impact>data from rabbit model</gtr:impact><gtr:outcomeId>aREDZCfjVmt-1</gtr:outcomeId><gtr:partnerContribution>Training in rabbit model of cryptococcal meningitis</gtr:partnerContribution><gtr:piContribution>Learning a new rabbit model of cryptococcal meningitis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Tihana Bicanic/ Neil Stone</gtr:description><gtr:id>B5BEEE0E-F977-4282-81FA-36DB3C424413</gtr:id><gtr:impact>in progress</gtr:impact><gtr:outcomeId>54621aeda79907.10380795-1</gtr:outcomeId><gtr:partnerContribution>Conduct of clinical trial in Africa</gtr:partnerContribution><gtr:piContribution>Supervision of Wellcome Trust Fellow (Neil Stone)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Arno Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Arno Therapeutics</gtr:description><gtr:id>9DC27576-867B-4A10-A262-33C83923EA66</gtr:id><gtr:impact>research contract under negotiation</gtr:impact><gtr:outcomeId>54613da382c839.47553892-1</gtr:outcomeId><gtr:partnerContribution>antifungal agent with anticryptococcal activity</gtr:partnerContribution><gtr:piContribution>Collaboration in negotiation</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Technology Sydney</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Ian Charles</gtr:description><gtr:id>ED4F5880-A5ED-4EB5-B309-9FD3BB737829</gtr:id><gtr:impact>Research grant in preparation</gtr:impact><gtr:outcomeId>54613ec99f1dd0.05432490-1</gtr:outcomeId><gtr:partnerContribution>New antifungal agents</gtr:partnerContribution><gtr:piContribution>Testing of a new agent with anti-cryptococcal activity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Amphotericin B Cochleates (Industrial Collaboration)</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Matinas Biosciences</gtr:fundingOrg><gtr:id>A25D2446-0C02-4C49-BDCD-89762F4E914A</gtr:id><gtr:outcomeId>58c15b1c55f8f3.81633307</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Funding to obtain preliminary data for a new antifungal compound</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Quadram Institute Bioscience</gtr:fundingOrg><gtr:id>1191D716-49A0-4929-8109-7846E8883813</gtr:id><gtr:outcomeId>56dc3e8f1c0265.63267694</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Experimental data used to design an definitive clinical trial</gtr:description><gtr:id>BAE1077D-0FD7-4330-8A68-464BD2D265F2</gtr:id><gtr:impact>Abbreviated regimens of amphotericin B will likely enable improved therapy in resource poor settings</gtr:impact><gtr:outcomeId>VTevMEEZ2im</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Clinical trial development</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Trial to determine the safety and efficacy of an abbreviated regimen of liposomal amphotericin B for cryptococcal meningitis (Phase II study). Planning now for a definitive Phase III study.</gtr:description><gtr:id>7657BC55-C755-4B93-ACAB-C83787BD9F26</gtr:id><gtr:impact>Clinical findings in Phase II predicted from experimental studies funded by MRC</gtr:impact><gtr:outcomeId>58c15cbe5309b7.22616478</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>AMBITION Clinical Trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>clinical trial to investigate the efficacy of an abbreviated regimen of liposomal amphotericin B</gtr:description><gtr:id>0A06B98D-83BA-471E-B80C-CE050BE5D77C</gtr:id><gtr:impact>this trial will facilitate the use of an effective antifungal agent in resource poor settings</gtr:impact><gtr:outcomeId>54624c36906cf4.57661160</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Clinical trial for cryptococcal meningitis</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>TFDA14/CTR/0004/1</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>a unique model of disease that is a faithful mimic of human pathogenesis</gtr:description><gtr:id>A44CDA3D-C89C-4666-8C1C-926BFA747B3F</gtr:id><gtr:impact>data generation, and generation of new peer reviewed publication</gtr:impact><gtr:outcomeId>rEuP8QdzXs5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Rabbit model of cryptococcal meningitis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>an in vitro model in which the concentration time profile of antibiotics in humans can be simulated</gtr:description><gtr:id>46E47DE3-962B-49CA-AD48-7A13D42C974C</gtr:id><gtr:impact>abstract submission and generation of scientific paper</gtr:impact><gtr:outcomeId>54621ec88cbb13.27249260</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Hollow Fibre Model of Infection</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>45202565-6D83-4F2A-BFA1-2B30D9DE57B6</gtr:id><gtr:title>Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f54b4d10725610bc2a73fc02bf9cf770"><gtr:id>f54b4d10725610bc2a73fc02bf9cf770</gtr:id><gtr:otherNames>Sudan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>doi_15220_C_00216_13</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>310DA0AC-D1F3-4C3E-A1CD-E828196ECA29</gtr:id><gtr:title>Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c9ea96d4f291ca5d38d0b793fa18406"><gtr:id>7c9ea96d4f291ca5d38d0b793fa18406</gtr:id><gtr:otherNames>Livermore J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>LixqUq9h13o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>721777A2-BBCE-47FA-A4B4-2BC4C4B8A8A9</gtr:id><gtr:title>AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4283539dd9281d1ac99318cee14dc930"><gtr:id>4283539dd9281d1ac99318cee14dc930</gtr:id><gtr:otherNames>Molefi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56dc383128f8f7.06999270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>216BBA4F-BFC3-4B36-9932-96B05B05B6C2</gtr:id><gtr:title>Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0c29292559a749b0887a7d83763c9bb"><gtr:id>c0c29292559a749b0887a7d83763c9bb</gtr:id><gtr:otherNames>O'Connor L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>doi_15220_dis_jit164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39FC90CD-606B-493E-9E0B-D6634C340ADD</gtr:id><gtr:title>Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5f31df91c3c146f91811b3feeed3920"><gtr:id>a5f31df91c3c146f91811b3feeed3920</gtr:id><gtr:otherNames>Lestner J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5aa72bb79b2725.59866574</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001760</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>